Oxurion (TG40) Stock Overview
A biopharmaceutical company, develops medicines to prevent blindness in Belgium. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
TG40 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0002 |
| 52 Week High | €0.23 |
| 52 Week Low | €0.0002 |
| Beta | 0.12 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.90% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| TG40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -1.4% |
| 1Y | -99.9% | -11.2% | 10.0% |
Return vs Industry: TG40 underperformed the German Biotechs industry which returned -11.7% over the past year.
Return vs Market: TG40 underperformed the German Market which returned 8.9% over the past year.
Price Volatility
| TG40 volatility | |
|---|---|
| TG40 Average Weekly Movement | 1,203.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: TG40's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TG40's weekly volatility has increased from 606% to 1203% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 11 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.
Oxurion NV Fundamentals Summary
| TG40 fundamental statistics | |
|---|---|
| Market cap | €490.69k |
| Earnings (TTM) | €1.96m |
| Revenue (TTM) | €2.00k |
Is TG40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TG40 income statement (TTM) | |
|---|---|
| Revenue | €2.00k |
| Cost of Revenue | €15.00k |
| Gross Profit | -€13.00k |
| Other Expenses | -€1.97m |
| Earnings | €1.96m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Apr 03, 2026
| Earnings per share (EPS) | 0.028 |
| Gross Margin | -650.00% |
| Net Profit Margin | 97,950.00% |
| Debt/Equity Ratio | -90.2% |
How did TG40 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 13:12 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oxurion NV is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Roderick Verhelst | Degroof Petercam |
| Divya Harikesh | Goldman Sachs |
| Steven Chesney | Goldman Sachs |